S&P 500   3,390.46 (-2.16%)
DOW   27,605.53 (-2.58%)
QQQ   280.81 (-1.38%)
AAPL   114.95 (-0.08%)
MSFT   211.74 (-2.08%)
FB   280.32 (-1.57%)
GOOGL   1,597.97 (-2.14%)
AMZN   3,209.41 (+0.16%)
TSLA   418.28 (-0.56%)
NVDA   533.94 (-1.78%)
BABA   307.85 (-0.67%)
CGC   18.79 (-4.76%)
GE   7.43 (-2.62%)
MU   52.05 (-1.51%)
AMD   82.34 (+0.46%)
T   27.27 (-1.98%)
F   8.03 (-1.59%)
ACB   4.44 (-5.13%)
GILD   59.48 (-2.15%)
NFLX   485.06 (-0.66%)
NIO   26.45 (-2.61%)
BA   161.10 (-3.74%)
DIS   124.48 (-3.02%)
S&P 500   3,390.46 (-2.16%)
DOW   27,605.53 (-2.58%)
QQQ   280.81 (-1.38%)
AAPL   114.95 (-0.08%)
MSFT   211.74 (-2.08%)
FB   280.32 (-1.57%)
GOOGL   1,597.97 (-2.14%)
AMZN   3,209.41 (+0.16%)
TSLA   418.28 (-0.56%)
NVDA   533.94 (-1.78%)
BABA   307.85 (-0.67%)
CGC   18.79 (-4.76%)
GE   7.43 (-2.62%)
MU   52.05 (-1.51%)
AMD   82.34 (+0.46%)
T   27.27 (-1.98%)
F   8.03 (-1.59%)
ACB   4.44 (-5.13%)
GILD   59.48 (-2.15%)
NFLX   485.06 (-0.66%)
NIO   26.45 (-2.61%)
BA   161.10 (-3.74%)
DIS   124.48 (-3.02%)
S&P 500   3,390.46 (-2.16%)
DOW   27,605.53 (-2.58%)
QQQ   280.81 (-1.38%)
AAPL   114.95 (-0.08%)
MSFT   211.74 (-2.08%)
FB   280.32 (-1.57%)
GOOGL   1,597.97 (-2.14%)
AMZN   3,209.41 (+0.16%)
TSLA   418.28 (-0.56%)
NVDA   533.94 (-1.78%)
BABA   307.85 (-0.67%)
CGC   18.79 (-4.76%)
GE   7.43 (-2.62%)
MU   52.05 (-1.51%)
AMD   82.34 (+0.46%)
T   27.27 (-1.98%)
F   8.03 (-1.59%)
ACB   4.44 (-5.13%)
GILD   59.48 (-2.15%)
NFLX   485.06 (-0.66%)
NIO   26.45 (-2.61%)
BA   161.10 (-3.74%)
DIS   124.48 (-3.02%)
S&P 500   3,390.46 (-2.16%)
DOW   27,605.53 (-2.58%)
QQQ   280.81 (-1.38%)
AAPL   114.95 (-0.08%)
MSFT   211.74 (-2.08%)
FB   280.32 (-1.57%)
GOOGL   1,597.97 (-2.14%)
AMZN   3,209.41 (+0.16%)
TSLA   418.28 (-0.56%)
NVDA   533.94 (-1.78%)
BABA   307.85 (-0.67%)
CGC   18.79 (-4.76%)
GE   7.43 (-2.62%)
MU   52.05 (-1.51%)
AMD   82.34 (+0.46%)
T   27.27 (-1.98%)
F   8.03 (-1.59%)
ACB   4.44 (-5.13%)
GILD   59.48 (-2.15%)
NFLX   485.06 (-0.66%)
NIO   26.45 (-2.61%)
BA   161.10 (-3.74%)
DIS   124.48 (-3.02%)
Log in
OTCMKTS:RHHVF

Roche Stock Forecast, Price & News

$327.31
-1.51 (-0.46 %)
(As of 10/23/2020 09:51 PM ET)
Add
Compare
Today's Range
$327.23
Now: $327.31
$331.09
50-Day Range
$328.82
MA: $352.05
$372.80
52-Week Range
$281.04
Now: $327.31
$399.00
Volume1,000 shs
Average Volume8,672 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anemia, cancer, cardiovascular, central nervous system, dermatology, hepatitis B and C, HIV/AIDS, inflammatory and autoimmune, intensive care medicine, leukemia, lymphoma, metabolic disorders, ophthalmology, respiratory disorders, rheumatoid arthritis, skin cancer, and transplantation. The company also offers in vitro diagnostics solutions for indications, such as cardiology, hematology, blood donor screening, coagulation, infectious disease, gynecology, oncology, and women's health. In addition, it supplies diagnostic instruments, reagents, consumables, and test kits for use in the diverse research market. Further, the company discovers, develops, and delivers gene therapies. Roche Holding AG has collaboration with Gilead Sciences, Inc. for COVID-19. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.58 out of 5 stars

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:RHHVF
CUSIPN/A
CIKN/A
Phone41 61 688 11 11
Employees97,735

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
$327.31
-1.51 (-0.46 %)
(As of 10/23/2020 09:51 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RHHVF News and Ratings via Email

Sign-up to receive the latest news and ratings for RHHVF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Roche (OTCMKTS:RHHVF) Frequently Asked Questions

How has Roche's stock been impacted by Coronavirus?

Roche's stock was trading at $318.96 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, RHHVF stock has increased by 2.6% and is now trading at $327.31.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Roche?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Roche in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Roche
.

What are Wall Street analysts saying about Roche stock?

Here are some recent quotes from research analysts about Roche stock:
  • 1. Jefferies Financial Group Inc. analysts commented, "NEW YORK (dpa-AFX Analyser) – Das Analysehaus Jefferies hat das Kursziel fur Roche von 370 auf 360 Franken gesenkt, die Einstufung aber auf Buy" belassen. Dies schrieb Analyst Peter Welford in einem am Mittwoch vorliegenden Ausblick zu den Quartalsberichten der Pharmabranche. Er bleibt zwar von den Schweizern uberzeugt, ist fur das erste Quartal aber eher zuruckhaltend./ag/kro Veroffentlichung der Original-Studie: 14.04.2020 / 14:27 / ET Erstmalige Weitergabe der Original-Studie: 14.04.2020 / 19:05 / ET Hinweis: Informationen zur Offenlegungspflicht bei Interessenkonflikten im Sinne von § 85 Abs. 1 WpHG, Art. 20 VO (EU) 596/2014 fur das genannte Analysten-Haus finden Sie unter http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html." (4/15/2020)
  • 2. Deutsche Bank Aktiengesellschaft analysts commented, "FRANKFURT (dpa-AFX Analyser) – Die Deutsche Bank hat die Einstufung fur Roche vor Zahlen auf Buy" mit einem Kursziel von 350 Franken belassen. Analyst Richard Parkes rechnet mit einem starken ersten Quartal des Pharmaherstellers. Verwerfungen wegen Covid-19 konne Roche anderweitig ausgleichen, schrieb er in einer am Montag vorliegenden Studie./ajx/jha/ Veroffentlichung der Original-Studie: 06.04.2020 / Uhrzeit in Studie nicht angegeben / GMT Erstmalige Weitergabe der Original-Studie: 06.04.2020 / 06:00 / GMT Hinweis: Informationen zur Offenlegungspflicht bei Interessenkonflikten im Sinne von § 85 Abs. 1 WpHG, Art. 20 VO (EU) 596/2014 fur das genannte Analysten-Haus finden Sie unter http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html." (4/7/2020)

Are investors shorting Roche?

Roche saw a increase in short interest in the month of September. As of September 30th, there was short interest totaling 552,800 shares, an increase of 617.0% from the September 15th total of 77,100 shares. Based on an average daily trading volume, of 3,500 shares, the days-to-cover ratio is currently 157.9 days.
View Roche's Short Interest
.

Who are some of Roche's key competitors?

Who are Roche's key executives?

Roche's management team includes the following people:
  • Dr. Severin Schwan, CEO & Exec. Director (Age 53)
  • Dr. Alan Hippe, Chief Financial & IT Officer (Age 53)
  • Dr. Karl Mahler, Head of Investor Relations
  • Dr. Urs Jaisli, Chief Compliance Officer (Age 64)
  • Ms. Claudia Böckstiegel, Gen. Counsel (Age 56)

What is Roche's stock symbol?

Roche trades on the OTCMKTS under the ticker symbol "RHHVF."

How do I buy shares of Roche?

Shares of RHHVF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Roche's stock price today?

One share of RHHVF stock can currently be purchased for approximately $327.31.

What is Roche's official website?

The official website for Roche is www.roche.com.

How can I contact Roche?

The company can be reached via phone at 41 61 688 11 11.

This page was last updated on 10/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.